Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ)
- Previous Close
2.3500 - Open
2.3300 - Bid 2.3300 x --
- Ask 2.3400 x --
- Day's Range
2.3200 - 2.3500 - 52 Week Range
2.0700 - 3.1900 - Volume
11,502,002 - Avg. Volume
20,862,736 - Market Cap (intraday)
6.131B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 16, 2019
- 1y Target Est
--
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and provides value-added services for hospitals, medical institutions, and drug retail institutions and distributors. The company offers drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1989 and is headquartered in Shenzhen, China.
www.neptunusbio.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000078.SZ
View MorePerformance Overview: 000078.SZ
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000078.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000078.SZ
View MoreValuation Measures
Market Cap
6.18B
Enterprise Value
13.28B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.21
Price/Book (mrq)
3.40
Enterprise Value/Revenue
0.45
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.94%
Return on Assets (ttm)
1.09%
Return on Equity (ttm)
-33.06%
Revenue (ttm)
30.32B
Net Income Avi to Common (ttm)
-1.19B
Diluted EPS (ttm)
-0.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
3.4B
Total Debt/Equity (mrq)
358.35%
Levered Free Cash Flow (ttm)
1.86B